<DOC>
	<DOCNO>NCT02500537</DOCNO>
	<brief_summary>A post-market study Endo GIA™ Reinforced Reload Tri-Staple™ Technology .</brief_summary>
	<brief_title>A Post-market Study Endo GIA™ Reinforced Reload With Tri-Staple™ Technology</brief_title>
	<detailed_description>The objective prospective , two-arm , multicenter , post-market study evaluate safety incidence report device-related adverse event ( AEs ) 30 day follow use Endo GIA™ Reinforced Reload Tri-Staple™ Technology subject undergoing indicated abdominal thoracic procedure .</detailed_description>
	<criteria>1 . The subject must 1880 year age 2 . The subject must willing able participate study procedure understand sign inform consent 3 . The subject undergoing indicate primary abdominal thoracic procedure Endo GIA™ Reinforced Reload TriStaple™ Technology ( Universal Handle ) use per Instructions For Use ( IFU ) Thoracic procedure may include , limited , wedge resection lobectomy , may include video assist thoracic surgery ( VATS ) open procedure . Abdominal procedure may include , limited , laparoscopic sleeve gastrectomy ( LSG ) , laparoscopic RouxenY gastric bypass ( LRYGB ) , biliopancreatic diversion , well hepatic pancreatic resection . 4 . For thoracic subject : subject FEV1 ≥40 % 1 . Subjects undergoing cardiac vascular procedure 2 . The procedure emergency procedure 3 . The procedure revision/reoperation indication 4 . Any female subject pregnant . Females childbearing potential require provide either urine pregnancy test serum pregnancy test ( except subject surgically sterile postmenopausal least two year ) 5 . Any subject consider part vulnerable population ( e.g . prisoner without sufficient mental capacity ) 6 . The subject unable unwilling comply study requirement followup schedule 7 . The subject comorbidities , opinion Investigator , appropriate study subject estimate life expectancy le 6 month 8 . The subject diagnose bleed disorder and/or undergo active reverse anticoagulant treatment 9 . The subject concurrently enrol investigational drug device research study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>